FAST LANE
10 Dec 2020
CodeBreak 100
NCT03600883
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced Solid Tumors
Amgen
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase I; Phase II |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | Advanced Solid Tumors |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2018-08-27 |
Anticipated End Date | 2024-03-08 |
Hospital | The Queen Elizabeth Hospital |
---|---|
Clinical Trial Coordinator | Pamela Cooper |
pamela.cooper@sa.gov.au | |
Phone | 08 8222 6410 |
Principal Investigator | Professor Tim Price |
Recruitment Status | Recruiting |